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Introduction: Worldwide, bacterial resistance to antibiotic therapy is a major concern for the 
medical community. Antibiotic resistance mainly affects Gram-negative bacteria that are an 
important cause of lower urinary tract infections (LUTIs). Pelvic irradiation for prostate cancer 
is a risk factor for LUTIs. Cranberry extract is reported to reduce the incidence of LUTIs. The 
prophylactic role of an enteric-coated, highly standardized cranberry extract (VO370®) in reduc-
ing LUTI episodes, urinary discomfort, and nonsteroidal anti-inflammatory drug (NSAID) and 
antibiotic use during radiotherapy for prostate carcinoma was evaluated.
Methods: A total of 924 patients with prostate carcinoma treated by radiotherapy to the 
prostatic and pelvic areas were randomized to receive (n=489) or not (n=435) the enteric-
coated, highly standardized cranberry extract for 6–7 weeks concurrently with irradiation. 
Outcomes were analyzed by using Mann–Whitney U test and Pearson’s c2 test. Primary 
endpoint was the number of patients with LUTI; secondary endpoints were incidence of 
recurrence, days of treatment with antibiotics and number of subjects treated with NSAIDs, 
and incidence of dysuria. 
Results: The treatment was very well tolerated, and there were no serious side effects. All enrolled 
patients completed the study. Urinary infections were detected in 53 of the 489 patients (10.8%) 
treated with enteric-coated, highly standardized cranberry extract, while 107 of the 435 patients 
(24.6%) in the control group developed LUTIs (p=0.0001). A clear and significant reduction in 
urinary discomfort of ~50% was seen in treated subjects. The treatment also resulted in ~50% 
reduction in the use of anti-inflammatory drugs and antibiotics. 
Conclusion: The enteric-coated, highly standardized cranberry extract could be used as a pro-
phylactic to reduce the incidence of LUTIs and decrease antibiotic therapy in patients receiving 
pelvic irradiation for prostate cancer.
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Introduction
The medical community is seriously concerned about the increasing resistance of bac-
teria, especially Gram-negative bacteria, to antibiotics,1 and innovative approaches are 
needed to deal with the problem. Strategies proposed include the use of phytochemicals 
to inhibit or eradicate biofilms, to interfere with bacterial quorum sensing signaling 
pathways, or to act as chelating agents and/or efflux pump inhibitors.2 A-type interfla-
vane bond proanthocyanidins (PAC-A) from Vaccinium macrocarpon (cranberry) fruit, 
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by interacting directly with P-type fimbrial structures found in 
uropathogenic Escherichia coli strains, seem to prevent their 
binding to the receptor glycoprotein located on the urinary 
bladder epithelium. This apparently limits the ability of the 
bacteria to adhere and, therefore, proliferate, thus preventing 
effective colonization and disease.3 Therefore, patients with 
repeated lower urinary tract infections (LUTIs) could pos-
sibly avoid recurrence by consuming cranberry preparations.4 
LUTI is also a possible adverse event during external beam 
radiotherapy (EBRT) to the pelvis,5 and E. coli is often the 
most common pathogen isolated in culture in these LUTIs.6,7 
Antibiotic-resistant strains have also been isolated in LUTIs 
caused by EBRT, and pathogens resistant to trimethoprim/
sulfamethoxazole, ciprofloxacin, and nitrofurantoin have 
been found through antibiotic sensitivity analysis.6 Since it 
has already been demonstrated that the use of enteric-coated, 
highly standardized cranberry extract is effective in reduc-
ing LUTIs caused by EBRT, with a significant reduction in 
urinary tract symptoms,7 the aim of the present work was to 
confirm the previous findings in a larger number of subjects 
and show that the preventive use of the same cranberry prepa-
ration can lead to a considerable decrease in antibiotic use. 
Methods
Study patterns
This randomized, open-label, controlled study was performed 
with the approval of the local Ethics Board of Cremona Hos-
pital (Cremona, Italy), and conducted during routine clinical 
practice, following international guidelines and in line with the 
principles outlined in the Declaration of Helsinki. All patients 
provided written informed consent to participate. Enrolment 
took place between 2006 and 2016 at the Radiation Oncology 
Unit of Cremona Hospital (ASST, Cremona, Italy). Patients 
(n=924) diagnosed with prostatic adenocarcinoma were treated 
with radiotherapy to the prostatic area and also to the pelvic 
area if the risk of lymph node (LN) spread was >15% accord-
ing to Kattan’s nomograms.8 Only patients treated with radical 
(73.6 Gy delivered as 32 fractions of 2.3 Gy, five fractions 
per week), postsurgical (66/69 Gy delivered as 32 fractions 
of 2.23/2.30 Gy, five fractions per week), or personalized (45 
Gy delivered as 15 fractions of 3 Gy, five fractions per week) 
radiotherapy were enrolled in the study. Of the 924 patients, 
479 had also undergone surgery. Patients with a history of 
pelvic EBRT, previous pelvic malignancies, a Karnofsky score9 
<80, renal failure, or refusal of preventive, daily treatment with 
cranberry extract were excluded from the study.
The patients were randomized into two groups by toss-
ing a coin. The treated group consisting of 489 patients was 
 administered one tablet/day containing 200 mg of cranberry 
extract for 6–7 weeks. The tested cranberry is an enteric-coated, 
highly standardized extract, titered as 30% PACs according to 
the European Pharmacopoeia method (version 6.0), and sold 
in Italy as MonoselectMacrocarpon® by PharmExtracta (Italy) 
and in the rest of the world as Ressuro® by Helsinn Integrative 
Care (Helsinn Healthcare SA, Switzerland). An enteric coating 
was used to prevent possible degradation of PAC-A during 
processing, and because of their instability in gastric juices 
and possible interaction with gastric Helicobacter pylori.10,11 
No particular suggestion was given to patients in terms of 
diet, except that the product should not be taken with meals. 
A second, untreated group of 435 subjects served as controls. 
No patients exhibited symptoms of cystitis at enrolment, and 
hence, no urine cultures were carried out at that time.
Radiotherapy was performed using 6 Mv photons with 
volumetric modulated arc therapy (VMAT) techniques. 
During treatment planning, the bladder volume and whole 
bladder average dose were recorded to assess the EBRT 
impact on urinary symptoms. During the treatment, all the 
patients underwent a weekly examination to assess urinary 
symptoms and determine nonsteroidal anti-inflammatory 
drug (NSAID) and antibiotic use. Two urine cultures were 
performed at week 3 and at week 6 of treatment, with a further 
culture performed on request in case of severe dysuria. A 
UTI was assumed when the findings of bacteriuria exceeded 
100,000 units/mL, accompanied by specific symptoms of 
cystitis. Bacterial species determination has been done by 
growing bacteria on the selected medium according to con-
ventional methods.12 The primary endpoint of the study was 
the number of patients who experienced episodes of LUTI 
in the two different groups. Secondary endpoints included 
incidence of recurrence, days of treatment with antibiotics 
(any antibiotic was administered for 5 days but ampicillin 
administered for 6 days) and number of subjects treated with 
NSAIDs, and incidence of dysuria in the two groups.
Statistical analysis
For statistical analysis, a preliminary data exploration was 
performed. Numerical variables were expressed as the median 
and range and were compared using nonparametric tests 
(Mann–Whitney U test). Qualitative data were expressed 
as frequencies and organized into contingency tables; the 
association between categorical variables was investigated 
by means of Pearson’s c2 test. Univariate logistic regression 
was performed to evaluate the influence of VO370® on the 
development of LUTIs. Significance was set at p< 0.05. 
STATA 13.1 software was used for analysis.
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Results
As shown in Table 1, the main characteristics of the two 
groups were comparable. The only significant difference 
was the higher percentage of subjects in the treated group 
(~50% vs 32%) who received both prostate and pelvic 
LN irradiation. The compliance of the treated group was 
excellent, and no patient discontinued treatment during the 
study. In the treated group, four patients with chronic gas-
tritis complained of gastric pain. This required the use of a 
protecting agent, but no other unpleasant, or allergic, effects 
were observed. All patients completed the planned EBRT. 
As shown in Table 2, 107 of the 435 patients (24.6%) in the 
control group experienced LUTIs compared to 53 of the 489 
patients in the treated group (10.8%; p=0.0001). In univari-
ate analysis, the use of cranberry was correlated with a low 
risk of developing a LUTI (odds ratio 0.39; 95% confidence 
interval [CI] 0.27–0.55). Recurrent infection was seen in 
10 patients (2.3%) in the control group and in four patients 
(0.8%) in the treated group (p=0.004).
E. coli was the main microorganism involved in LUTIs. 
Of the 75 cases in the two groups, 54 (72%) were in the 
control group and 21 (28%) in the treated group. Entero-
coccus faecalis was involved in 37 cases of LUTI, with 21 
such cases (~57%) in the untreated group and 16 (43%) in 
the treated group. With a few exceptions (ie, Staphylococ-
cus hominis, Proteus mirabilis, and Acinetobacter spp.), 
all other microorganisms were found less frequently in the 
treated group than in the control group. Their relatively small 
number does not allow statistically significant differences 
to be identified.
As shown in Table 3, the drop in LUTI incidence in 
the treated group resulted in a reduction in antibiotic use. 
Cranberry-treated subjects (n=489) were administered an 
antibiotic for a total of 285 days compared to 585 days in 
the control group (n=435), showing that cranberry adminis-
tration significantly reduced (–48.7%) the use of antibiotics 
(p=0.001).
A considerable reduction in dysuria (Table 4) was also 
seen in the cranberry-treated subjects. Assessment with the 
Boyarsky scoring system for dysuria discomfort13 revealed an 
absence of symptoms in ~63% of treated subjects compared 
to ~37% of the control group. Occasional burning, frequent 
burning, and constant pain, respectively, were observed in 
Table 1 Characteristics of the 924 subjects enrolled in the study
Treated 
(n=489)
Untreated 
(n=435)
p-value
Age (years) 69.63±7.16 70.15±6.45 0.25
Karnofsky score 91.43±4.99 92.59±5.71 0.27
Diabetes (%) 13.50 12.18 0.55
Irradiation
73.6 Gya (%) 54.60 59.08 0.26
66/69 Gyb (%) 43.35 39.77 0.31
45 Gyc (%) 2.05 1.15 0.17
Prostated (%) 50.10 67.82 0.001
Prostate + LNe (%) 49.90 32.18 0.001
Surgery (%) 54.60 48.74 0.28
Notes: aRadical prostate irradiation (2.3 Gy/fraction/day). bPostsurgical (adjuvant 
or salvage) irradiation (2.2/2.30 Gy/fraction/day). cPersonalized irradiation (3 Gy/
fraction/day) to prostate and nearby areas. dOnly prostate or prostatic lodge 
irradiation. eProstate and pelvic lymph node (LN) irradiation.
Table 3 Days of treatment with antibiotics and number of 
subjects treated with nonsteroidal anti-inflammatory drugs 
(NSAIDs) in the two groups
Treated 
(n=489)
Untreated 
(n=435)
D% p-value
Antibioticsa 285 585 –48.7 0.001
NSAIDsb 113 201 –56.2 0.001
Notes: aCiprofloxacin, nitrofurantoin, amoxicillin plus clavulanic acid. bNimesulide, 
ibuprofen, and, in case of fever, acetaminophen.
Table 2 Frequency, type of urinary infection, and relapses in the 
treatment and control groups
Microorganism Treated 
(n=489)
Untreated 
(n=435)
p-value
Events  
(n)
% Events  
(n)
%
Escherichia coli 21 39.6 54 50.5 0.002
Enterococcus faecalis 16 30.2 21 19.6 0.04
Enterobacter cloacae 2 3.8 3 2.8 n.s.
Pseudomonas aeruginosa 1 1.9 5 4.7 n.s.
Streptococcus agalactiae 3 5.7 4 3.7 n.s.
Staphylococcus 
hominis
2 3.8 0 0 n.s.
Klebsiella pneumoniae 1 1.9 2 1.9 n.s.
Klebsiella oxitoca 2 3.8 3 2.8 n.s.
Proteus mirabilis 3 5.7 0 0 n.s.
Citobacter koseri 1 1.9 4 3.7 n.s.
Acinetobacter spp. 1 1.9 0 0 n.s.
Staphylococcus epidermidis 0 0 2 1.9 n.s.
Streptococcus constellatus 0 0 1 0.9 n.s.
Serratia marcescens 0 0 1 0.9 n.s.
Staphylococcus 
haemolyticus
0 0 1 0.9 n.s.
Not known 0 0 6 5.6 0.04
Totala 53 100 107 100 0.0001
Relapsesb 4 0.82 10 2.3 0.04
Notes: aConsidering all bladder infections (odds ratio 0.39; 95% CI 0.27–0.55). bIn 
all relapses, the microorganism involved was the same as in the first episode except 
for two cases among untreated subjects where E. faecalis relapsed after E. coli, and P. 
mirabilis relapsed after P. aeruginosa, and one case among treated subjects where E. 
coli and Acinetobacter spp. relapsed after E. faecalis.
Abbreviations: n.s., not significant; CI, confidence interval.
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~26%, 10%, and 0.6% of the treated group and in ~33%, 
24%, and 7% of the control group.
NSAIDs are routinely prescribed to treat urinary symp-
toms. As shown in Table 3, NSAIDs were used by 201 of the 
435 subjects in the control group (46.2%) and by 113 of the 
489 subjects in the treated group (23.1%). This demonstrates 
that cranberry administration significantly reduced (–56.2%) 
the use of NSAIDs.
Finally, urinary symptoms due to radiotherapy were 
milder in the treated subjects compared to controls. Nocturia 
affected 29% of treated subjects and 52% of control subjects, 
urgency affected 30% of treated subjects and 55% of control 
subjects, and average daily urination frequency increased 
from 5.65 to 7.45 in the treated group and from 5.22 to 8.57 
in the control group (data not shown).
Conclusion
Cystitis is a common infection, affecting 0.5%–1% of the 
population. About 90% of bladder infections are caused by 
Gram-negative bacteria, especially of fecal origin, and >50% 
of these Gram-negative infections are caused by E. coli, with 
Enterococcus, Pseudomonas, Enterobacter, Klebsiella, and 
Proteus spp. less frequent.14–16 Also, microorganisms causing 
LUTIs can demonstrate resistance due to the excessive use 
of antibiotics. Indeed, LUTI shows a high frequency (20%) 
of relapse in some populations, such as menopausal women, 
despite the use of antibiotics.14 Cancer patients treated with 
pelvic radiotherapy are at increased risk of urinary infections, 
with an incidence ranging from 14% to 33%, depending on 
the type of cancer and radiation techniques used.17–20
In a previous work, it was demonstrated that the use of 
an enteric-coated, highly standardized cranberry extract 
decreased the incidence and symptoms of LUTI caused by 
irradiation in prostate cancer patients.7 The aim of the current 
work was to confirm the previous findings in a larger sample 
of subjects while also evaluating the reduction in antibiotic 
use following cranberry treatment. Indeed, the results of 
this study, independently from Gy intensity used (data not 
shown), demonstrate once again the beneficial role played by 
enteric-coated cranberry extract in preventing LUTI episodes 
(objective endpoint) and in reducing urinary discomfort, 
such as dysuria, nocturia, and urinary frequency (subjective 
endpoints). There were 53 patients with LUTIs in the treated 
group compared to 107 in the control group, while 113 sub-
jects in the treated group were treated with NSAIDs compared 
to 210 in the control group. These differences clearly indi-
cate that the treatment with enteric-coated cranberry could 
lessen actinic damage to the bladder mucosa, thus reducing 
the inflammatory process and, consequently, symptoms in 
those subjects apparently not having a LUTI. Moreover, for 
the first time, this study demonstrates that the prophylactic 
use of cranberry can reduce antibiotic treatment by ~50% 
with advantages in terms of possible reduced generation of 
new antibiotic resistance.
This work has some limitations. In particular, it is not 
a double-blind, placebo-controlled trial. Moreover, despite 
the randomization process, there is a significant potential 
that the patients with prostate + LN field radiation (Table 1) 
had higher risk of LUTI and dysuria. However, it was a 
study with a considerable number of subjects and a control 
group. Statistical analysis shows that preventive treatment 
with an enteric-coated and highly standardized cranberry 
extract reduces the incidence of LUTI, its symptoms, and 
antibiotic and NSAID use. Further studies are currently 
ongoing to validate these findings in a blinded study with 
a placebo.
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